The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 in the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial.’ (Abstract number: 1009) was presented at the ACR Convergence, November 10–14, 2022.
Disclosures: Sofia Ramiro discloses receiving grant/ research support from AbbVie, Galapagos, Novartis, Pfizer, and UCB; and honoraria from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Poster reprinted from ACR Convergence held November 10–14, 2022. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Touch Medical Media Ltd.
Share this Video
Related Videos In Axial Spondyloarthritis
Axial spondyloarthritis treatment paradigm and unmet needs: Fabian Proft, EULAR 2023
Axial spondyloarthritis is a chronic, inflammatory rheumatic disease that affects the axial skeleton, causing severe pain, stiffness and fatigue. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about the treatment paradigm and unmet needs of axial spondyloarthritis. The abstract ‘Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with […]
BE MOBILE 1 and BE MOBILE 2: phase 3 studies of bimekizumab in axial spondyloarthritis: Fabian Proft, EULAR 2023
BE MOBILE 1 and BE MOBILE 2 are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axial spondyloarthritis spectrum. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about these trials and his poster on the maintenance […]
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!